糖尿病状态与肾下腹主动脉瘤开放及腔内修复术后长期结局的关系
基于血管质量倡议登记与Medicare理赔链接数据,纳入2003至2018年肾下腹主动脉瘤行开放修复(4127例)或腔内修复(34021例)患者。糖尿病与腔内修复术后8年破裂风险降低相关(HR 0.68),但与非胰岛素降糖药管理者破裂风险更低;糖尿病与两种修复术后8年全因死亡风险升高相关。
要点
- 腔内修复患者中20%有糖尿病,开放修复患者中16%有糖尿病。
- 糖尿病患者腔内修复术后瘤囊稳定更常见,非糖尿病患者瘤囊回缩更常见。
- 糖尿病与两种修复术后8年全因死亡风险升高相关。
核心结论
- 糖尿病与非胰岛素降糖药管理的患者中,腔内修复及开放修复术后8年破裂调整风险更低。
- 与无腹主动脉瘤患者一样,术前糖尿病与8年全因死亡调整风险升高相关。
- 需进一步研究评估糖尿病与非糖尿病患者动脉瘤相关死亡的差异,并计划研究非胰岛素降糖药对动脉瘤相关结局的独立效应。
研究设计与样本
- 基于血管质量倡议登记数据与Medicare理赔链接,纳入2003至2018年因肾下腹主动脉瘤行开放修复或腔内修复的患者。
- 排除糖尿病状态缺失者,按术前糖尿病状态分层,再按饮食、非胰岛素降糖药或胰岛素管理分层。
- 腔内修复组34021例,开放修复组4127例;糖尿病比例分别为20%和16%。
- 糖尿病患者中22%为饮食管理,59%为非胰岛素降糖药,19%为胰岛素。
- 采用χ2检验、Kaplan-Meier法和多变量Cox回归分析1年瘤囊动态、8年破裂、再干预和全因死亡。
主要发现
- 腔内修复术后1年,糖尿病患者瘤囊稳定更常见,非糖尿病患者瘤囊回缩更常见。
- 腔内修复术后8年破裂风险:糖尿病 vs 非糖尿病 HR 0.68(95%CI 0.51-0.92)。
- 8年破裂风险:非胰岛素降糖药 vs 非糖尿病 腔内修复 HR 0.64(95%CI 0.44-0.94)、开放修复 HR 0.29(95%CI 0.41-0.80);饮食控制和胰岛素与非糖尿病破裂风险相似。
- 8年全因死亡风险:糖尿病 vs 非糖尿病 腔内修复 HR 1.17(95%CI 1.11-1.23)、开放修复 HR 1.16(95%CI 1.00-1.36)。
- 8年全因死亡风险:非胰岛素降糖药 vs 非糖尿病 腔内修复 HR 1.12(95%CI 1.05-1.20)、开放修复 HR 1.27(95%CI 1.06-1.54);胰岛素 vs 非糖尿病 腔内修复 HR 1.40(95%CI 1.26-1.55)、开放修复 HR 1.57(95%CI 1.15-2.13);再干预风险在糖尿病与非糖尿病间相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步研究评估糖尿病与非糖尿病患者动脉瘤相关死亡的差异。
- 研究计划评估非胰岛素降糖药对动脉瘤相关结局的独立效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Current literature reports conflicting findings regarding the effect of diabetes mellitus (DM) on outcomes of abdominal aortic aneurysm (AAA) repair. In this study we examined the effect of DM and its management on outcomes after open AAA repair (OAR) and endovascular AAA repair (EVAR). METHODS: We identified all patients undergoing OAR or EVAR for infrarenal AAA between 2003 and 2018 in the Vascular Quality Initiative registry data linked with Medicare claims. We excluded patients with missing DM status. Patients were stratified by their preoperative DM status, and then further stratified by DM management: dietary, noninsulin antidiabetic medications (NIMs), or insulin. Outcomes of interest included 1-year aneurysm sac dynamics, 8-year aneurysm rupture, reintervention, and all-cause mortality. These outcomes were analyzed with the χ2 test, Kaplan-Meier methods, and multivariable Cox regression analyses. RESULTS: We identified 34,021 EVAR patients and 4127 OAR patients, of whom 20% and 16% had DM, respectively. Of all DM patients, 22% were managed by dietary management, 59% by NIM, and 19% by insulin. After EVAR, DM patients were more likely to have stable sacs, whereas non-DM patients were more likely to have sac regression at 1 year. Compared with non-DM, DM was associated with a significantly lower risk for 8-year rupture in EVAR (EVAR hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.51-0.92). Compared with non-DM, NIM was associated with lower risk of rupture within 8-years for both EVAR and OAR (EVAR HR, 0.64; 95% CI, 0.44-0.94; OAR HR, 0.29; 95% CI, 0.41-0.80), whereas dietary control and insulin had a similar rupture risk compared with non-DM. However, compared with non-DM, DM was associated with a higher risk of 8-year all-cause mortality after EVAR and OAR (DM vs non-DM: EVAR HR, 1.17; 95% CI, 1.11-1.23; OAR HR, 1.16; 95% CI, 1.00-1.36). After further DM management substratification, compared with non-DM, management with NIM and insulin were associated with a higher 8-year mortality in EVAR and OAR (EVAR: NIM HR, 1.12; 95% CI, 1.05-1.20; insulin: HR, 1.40; 95% CI, 1.26-1.55; OAR: NIM HR, 1.27; 95% CI, 1.06-1.54; and insulin: HR, 1.57; 95% CI, 1.15-2.13). Finally, there was a similar risk of reintervention across the DM and non-DM populations for EVAR and OAR. CONCLUSIONS: DM was associated with a lower adjusted risk of rupture after EVAR as well as OAR in patients managed with NIM. Nevertheless, just as in patients without AAA, preoperative DM was associated with a higher adjusted risk of all-cause mortality. Further study is needed to evaluate for differences in aneurysm-related mortality between DM and non-DM patients, and studies are planned to evaluate the independent effect of NIM on aneurysm-related outcomes.
引用
- Rastogi V, Summers SP, Yadavalli SD, et al. Association between diabetes status and long-term outcomes following open and endovascular repair of infrarenal abdominal aortic aneurysms. J Vasc Surg. 2024. PMID: 39181338. doi:10.1016/j.jvs.2024.08.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。